Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETLRCX$190.20-31.08(-14.05%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ETPTGX$135.26-8.19(-5.71%)Protagonist Therapeutics Q3 revenue surges on Takeda payments4:48:48 PM ETBAC$49.84-1.80(-3.49%)MEDIA-BofA Rejigs Global Credit Trading Businesses To Boost Liquidity - Bloomberg News4:43:14 PM ETMNKD$3.66-0.28(-7.11%)MannKind Q3 revenue rises on royalty gains4:43:13 PM ETMSFT$531.00-25.01(-4.50%)Microsoft Q3 Earnings: The Only Top AI Hyperscaler Generating Positive FCF (Rating Downgrade)4:42:33 PM ETNVDA$182.36-17.93(-8.95%)Thursday's Final Takeaways: Mortgage Rates Continue Decline, NVDA Chips to China4:34:31 PM ETNVDA$182.36-17.93(-8.95%)Nvidia Plunges 9% as AI Selloff Wipes Out $2.3 Trillion | Closing Bell4:32:42 PM ETKLAC$130.03-19.62(-13.11%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$669.50-125.96(-15.83%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$669.50-125.96(-15.83%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.70-0.18(-0.19%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.74-22.24(-9.23%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$182.36-17.93(-8.95%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$190.20-31.08(-14.05%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$124.98-18.10(-12.65%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$182.36-17.93(-8.95%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$340.35-44.83(-11.64%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ETGOOGL$279.90-9.13(-3.16%)Google plans $17 billion Wyoming data center amid rising threats of curbs3:43:13 PM ETNOW$100.57-8.34(-7.66%)Arista Networks vs. ServiceNow: Which Technology Stock Is a Better Buy for 2027?3:43:02 PM ETGOOGL$279.90-9.13(-3.16%)BREAKINGVIEWS-Global muscle will sift puny data center providers3:30:09 PM ETAMD$411.45-77.24(-15.81%)Is AMD Stock a Buy as AI Revenue Soars?3:19:00 PM ETGEV$770.00-62.51(-7.51%)GE Vernova vs. NextEra Energy: Which Industrials Stock Is a Better Buy for 2027?3:17:11 PM ETBRK-A$857,487.54-9,063.79(-1.05%)Berkshire Hathaway Reports Nov. 7 With Its Stock at a Record. Its Cash Pile Is the Number to Watch.3:17:02 PM ET

VERA · NASDAQ

Vera Therapeutics, Inc.

$29.00 -2.99 (-9.35%)

Company overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections that is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.1B
Employees
152
Headquarters
Brisbane, CA
Website
veratx.com
CEO
Gary Barrera
Listed
May 14, 2021
P/E
-5.23
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$308,000
Operating income
-$383M
EBITDA
-$363M
Net income
-$369M
EPS
-$5.54
Total assets
$622M
Total debt
$75M
Earnings yield
-19.10%

Price chart

25.6430.6335.6240.6245.61
VERA 1D NASDAQ O31.00H32.18L30.73C31.97+1.26 (+4.10%)Vol1.99M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
VERAVera Therapeutics, Inc. Stock news Vera Therapeutics Q3 loss narrows, beats analyst estimates Reuters
VERAVera Therapeutics, Inc. Stock news BRIEF-Vera Therapeutics Q3 Net Income USD -93.711 Million Vs. IBES Estimate USD -117.1 Million Reuters
VERAVera Therapeutics, Inc. Press release Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results GlobeNewswire
VERAVera Therapeutics, Inc. Press release Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference GlobeNewswire
VERAVera Therapeutics, Inc. Stock news Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results MarketBeat
VERAVera Therapeutics, Inc. Stock news Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript Seeking Alpha
VERAVera Therapeutics, Inc. Press release Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine GlobeNewswire
VERAVera Therapeutics, Inc. Press release Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast GlobeNewswire
VERAVera Therapeutics, Inc. Press release Vera Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire
VERAVera Therapeutics, Inc. Press release Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 GlobeNewswire
VERAVera Therapeutics, Inc. Stock news Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
VERAVera Therapeutics, Inc. Stock news What's Going on With Vera Therapeutics Stock on Tuesday? Benzinga
VERAVera Therapeutics, Inc. Stock news Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results Barrons
VERAVera Therapeutics, Inc. Stock news Why is Vera Therapeutics stock reversing its premarket gains? Invezz
VERAVera Therapeutics, Inc. Stock news Vera Stock Slides Despite Positive Phase 3 Results Schaeffers Research
VERAVera Therapeutics, Inc. Press release Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy GlobeNewswire
VERAVera Therapeutics, Inc. Press release Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
VERAVera Therapeutics, Inc. Press release Vera Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire
VERAVera Therapeutics, Inc. Stock news Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy Seeking Alpha
VERAVera Therapeutics, Inc. Stock news Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch MarketBeat
See more
FAQ

Questions about Vera Therapeutics, Inc.

What does Vera Therapeutics, Inc. do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections that is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
What is VERA's market cap?
Vera Therapeutics, Inc. (VERA) is a listed stock with a live quote. The latest market cap on this page is $2.1B.
Where is Vera Therapeutics, Inc. headquartered?
Vera Therapeutics, Inc. is headquartered in Brisbane, CA.
How do I get VERA news from the API?
Call GET /v1/news?tickers=VERA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does VERA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VERA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the VERA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs